Figure 1.

Mean change in weight in the 24 months prior to and after antiretroviral therapy switch in participants with ≥10% weight gain postbaseline after switch to only tenofovir alafenamide (TAF) (n = 136), only integrase strand transfer inhibitor (INSTI) (n = 279), or both TAF and INSTI (n = 132). Mean change in weight in absolute kilograms was adjusted for baseline age, baseline weight, sex, and region of origin. Predicted values and standard errors were calculated and used to plot mean change in weight over time with 95% confidence interval.